Lamin B2 contributes to the proliferation of bladder cancer cells via activating the expression of cell division cycle‑associated protein 3

Ji,Junpeng; Li,Huibing; Chen,Jing; Wang,Wenjun

doi:10.3892/ijmm.2022.5168

Lamin B2 contributes to the proliferation of bladder cancer cells via activating the expression of cell division cycle‑associated protein 3

Authors:
- Junpeng Ji
- Huibing Li
- Jing Chen
- Wenjun Wang
View Affiliations

Affiliations: Department of Urology Surgery, The Third Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan 471003, P.R. China, Department of Urology Surgery, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan 471003, P.R. China, Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin 300060, P.R. China
Published online on: June 29, 2022 https://doi.org/10.3892/ijmm.2022.5168
Article Number: 111
Copyright: © Ji et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bladder cancer is the most common malignant tumor of the urinary system, and in China it is first among urogenital system tumors. More therapeutic targets are still urgently required to combat this disease. Lamin B2 (LMNB2) is a type of nuclear lamina filament protein, which is involved in multiple cellular processes, and known as an oncogene affecting the progression of multiple types of cancers. Although the multiple effects of LMNB2 on cancer progression have been elucidated, its possible role in bladder cancer remains unclear. In the present study, it was determined that LMNB2 expression was upregulated in human bladder cancer tissues, and its expression was correlated with the prognosis and the clinical features, including tumor stage (P=0.001) and recurrence (P=0.006) of patients with bladder cancer. In addition, it was further revealed that LMNB2 depletion inhibited bladder cancer cell proliferation, stimulated cell cycle arrest and apoptosis in vitro, and suppressed tumor growth of bladder cancer cells in mice. Furthermore, the present data revealed that LMNB2 promoted the proliferation of bladder cancer cells via transcriptional activation of CDCA3 expression. Therefore, the role of LMNB2 in bladder cancer progression was demonstrated, and may serve as a promising therapeutic target for bladder cancer treatment.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Zhang L, Liang J, Liu X, Wu J, Tan D and Hu W: Aloperine exerts antitumor effects on bladder cancer in vitro. Onco Targets Ther. 13:10351–10360. 2020. View Article : Google Scholar : PubMed/NCBI
3	Jian Y, Xu Z, Xu C, Zhang L, Sun X, Yang D and Wang S: The roles of glycans in bladder cancer. Front Oncol. 10:9572020. View Article : Google Scholar : PubMed/NCBI
4	El-Hefnawy AS, Rizk E, Al Demerdash Khamis NM, Barakat MAA, Khater SM and Shokeir AA: Urinary hyaluronic acid: A versatile marker of bladder cancer. Int Urol Nephrol. 52:1691–1699. 2020. View Article : Google Scholar : PubMed/NCBI
5	Dal Moro F, Valotto C, Guttilla A and Zattoni F: Urinary markers in the everyday diagnosis of bladder cancer. Urologia. 80:265–275. 2013. View Article : Google Scholar
6	Tao K, Liu S, Wang L, Qiu H, Li B, Zhang M, Guo M, Liu H, Zhang X, Liu Y, et al: Targeted multifunctional nanomaterials with MRI, chemotherapy and photothermal therapy for the diagnosis and treatment of bladder cancer. Biomater Sci. 8:342–352. 2019. View Article : Google Scholar : PubMed/NCBI
7	Payumo AY and Huang GN: Lamin B2, guardian of cardiomyocyte nuclear division. Dev Cell. 53:5–7. 2020. View Article : Google Scholar : PubMed/NCBI
8	Ranade D, Koul S, Thompson J, Prasad KB and Sengupta K: Chromosomal aneuploidies induced upon Lamin B2 depletion are mislocalized in the interphase nucleus. Chromosoma. 126:223–244. 2017. View Article : Google Scholar :
9	Kuga T, Nie H, Kazami T, Satoh M, Matsushita K, Nomura F, Maeshima K, Nakayama Y, Tomonaga T and Lamin B: 2 prevents chromosome instability by ensuring proper mitotic chromosome segregation. Oncogenesis. 3:e942014. View Article : Google Scholar
10	Han L, Choudhury S, Mich-Basso JD, Ammanamanchi N, Ganapathy B, Suresh S, Khaladkar M, Singh J, Maehr R, Zuppo DA, et al: Lamin B2 levels regulate polyploidization of cardiomyocyte nuclei and myocardial regeneration. Dev Cell. 53:42–59.e11. 2020. View Article : Google Scholar : PubMed/NCBI
11	Razafsky D, Ward C, Potter C, Zhu W, Xue Y, Kefalov VJ, Fong LG, Young SG and Hodzic D: Lamin B1 and lamin B2 are long-lived proteins with distinct functions in retinal development. Mol Biol Cell. 27:1928–1937. 2016. View Article : Google Scholar : PubMed/NCBI
12	Parry DA, Martin CA, Greene P, Marsh JA; Genomics England Research Consortium; Blyth M, Cox H, Donnelly D, Greenhalgh L, Greville-Heygate S, et al: Heterozygous lamin B1 and lamin B2 variants cause primary microcephaly and define a novel laminopathy. Genet Med. 23:408–414. 2021. View Article : Google Scholar :
13	Galazis N, Olaleye O, Haoula Z, Layfield R and Atiomo W: Proteomic biomarkers for ovarian cancer risk in women with polycystic ovary syndrome: A systematic review and biomarker database integration. Fertil Steril. 98:1590–1601.e1. 2012. View Article : Google Scholar : PubMed/NCBI
14	Zhang MY, Han YC, Han Q, Liang Y, Luo Y, Wei L, Yan T, Yang Y, Liu SL and Wang EH: Lamin B2 promotes the malignant phenotype of non-small cell lung cancer cells by upregulating dimethylation of histone 3 lysine 9. Exp Cell Res. 393:1120902020. View Article : Google Scholar : PubMed/NCBI
15	Kong W, Wu Z, Yang M, Zuo X, Yin G and Chen W: LMNB2 is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma. IUBMB Life. 72:2672–2685. 2020. View Article : Google Scholar : PubMed/NCBI
16	Ma Y, Fei L, Zhang M, Zhang W, Liu X, Wang C, Luo Y, Zhang H and Han Y: Lamin B2 binding to minichromosome maintenance complex component 7 promotes non-small cell lung carcinogenesis. Oncotarget. 8:104813–104830. 2017. View Article : Google Scholar : PubMed/NCBI
17	Abdelbaqi K and Di Paola D: Ku protein levels, localization and association to replication origins in different stages of breast tumor progression. J Cancer. 4:358–370. 2013. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
19	Cancer Genome Atlas Research Network: Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 499:43–49. 2013. View Article : Google Scholar : PubMed/NCBI
20	Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, et al: Laird, cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell. 173:291–304.e6. 2018. View Article : Google Scholar
21	Zou RC, Guo ZT, Wei D, Shi ZT, Ye ZC, Zhai G, Zhong C, Tang B, Wang L and Ge JY: Downregulation of CDCA3 expression inhibits tumor formation in pancreatic cancer. Neoplasma. 67:1223–1232. 2020. View Article : Google Scholar : PubMed/NCBI
22	Qian W, Zhang Z, Peng W, Li J, Gu Q, Ji D, Wang Q, Zhang Y, Ji B, Wang S, et al: CDCA3 mediates p21-dependent proliferation by regulating E2F1 expression in colorectal cancer. Int J Oncol. 53:2021–2033. 2018.PubMed/NCBI
23	Nguyen EK, Yu H, Pond G, Shayegan B, Pinthus JH, Kapoor A, Mukherjee SD, Neville A, Lalani AA, Hotte SJ, et al: Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer. Can Urol Assoc J. 14:122–129. 2020.
24	Pearce S and Daneshmand S: Enhanced endoscopy in bladder cancer. Curr Urol Rep. 19:842018. View Article : Google Scholar : PubMed/NCBI
25	De Keukeleire S, De Maeseneer D, Jacobs C and Rottey S: Targeting FGFR in bladder cancer: Ready for clinical practice? Acta Clin Belg. 75:49–56. 2020. View Article : Google Scholar
26	Vartolomei L, Ferro M, Mirone V, Shariat SF and Vartolomei MD: Systematic review: Depression and anxiety prevalence in bladder cancer patients. Bladder Cancer. 4:319–326. 2018. View Article : Google Scholar : PubMed/NCBI
27	Coffinier C, Fong LG and Young SG: LINCing lamin B2 to neuronal migration: Growing evidence for cell-specific roles of B-type lamins. Nucleus. 1:407–411. 2010. View Article : Google Scholar
28	Hegele RA, Cao H, Liu DM, Costain GA, Charlton-Menys V, Rodger NW and Durrington PN: Sequencing of the reannotated LMNB2 gene reveals novel mutations in patients with acquired partial lipodystrophy. Am J Hum Genet. 79:383–389. 2006. View Article : Google Scholar : PubMed/NCBI
29	Damiano JA, Afawi Z, Bahlo M, Mauermann M, Misk A, Arsov T, Oliver KL, Dahl HH, Shearer AE, Smith RJ, et al: Mutation of the nuclear lamin gene LMNB2 in progressive myoclonus epilepsy with early ataxia. Hum Mol Genet. 24:4483–4490. 2015. View Article : Google Scholar : PubMed/NCBI
30	Puzzi L, Marchetti L, Peverali FA, Biamonti G and Giacca M: DNA-protein interaction dynamics at the Lamin B2 replication origin. Cell Cycle. 14:64–73. 2015. View Article : Google Scholar :
31	Giusti L, Da Valle Y, Bonotti A, Donadio E, Ciregia F, Ventroni T, Foddis R, Giannaccini G, Guglielmi G, Cristaudo A and Lucacchini A: Comparative proteomic analysis of malignant pleural mesothelioma evidences an altered expression of nuclear lamin and filament-related proteins. Proteomics Clin Appl. 8:258–268. 2014. View Article : Google Scholar : PubMed/NCBI
32	Zhang Y, Yin W, Cao W, Chen P, Bian L and Ni Q: CDCA3 is a potential prognostic marker that promotes cell proliferation in gastric cancer. Oncol Rep. 41:2471–2481. 2019.PubMed/NCBI
33	Adams MN, Burgess JT, He Y, Gately K, Snell C, Zhang SD, Hooper JD, Richard DJ and O'Byrne KJ: Expression of CDCA3 is a prognostic biomarker and potential therapeutic target in non-small cell lung cancer. J Thorac Oncol. 12:1071–1084. 2017. View Article : Google Scholar : PubMed/NCBI
34	Zhang W, Lu Y and Li X, Zhang J, Zheng L, Zhang W, Lin C, Lin W and Li X: CDCA3 promotes cell proliferation by activating the NF-κB/cyclin D1 signaling pathway in colorectal cancer. Biochem Biophys Res Commun. 500:196–203. 2018. View Article : Google Scholar : PubMed/NCBI
35	Li S, Liu X, Liu T, Meng X, Yin X, Fang C, Huang D, Cao Y, Weng H, Zeng X and Wang X: Identification of biomarkers correlated with the TNM staging and overall survival of patients with bladder cancer. Front Physiol. 8:9472017. View Article : Google Scholar : PubMed/NCBI